Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats.

Cha JJ, Kang YS, Hyun YY, Han SY, Jee YH, Han KH, Han JY, Cha DR.

Life Sci. 2013 Jun 21;92(23):1118-24. doi: 10.1016/j.lfs.2013.04.008. Epub 2013 Apr 30.

PMID:
23643633
2.

Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats.

Cha DR, Kang YS, Han SY, Jee YH, Han KH, Han JY, Kim YS, Kim NH.

J Endocrinol. 2004 Oct;183(1):183-94.

3.

Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property.

Nam SM, Lee MY, Koh JH, Park JH, Shin JY, Shin YG, Koh SB, Lee EY, Chung CH.

Diabetes Res Clin Pract. 2009 Feb;83(2):176-82. doi: 10.1016/j.diabres.2008.10.007. Epub 2008 Dec 25.

PMID:
19111363
4.

Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.

Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR.

Nephrol Dial Transplant. 2009 Jan;24(1):73-84. doi: 10.1093/ndt/gfn448. Epub 2008 Aug 5.

6.

Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats.

Lee MY, Lee EY, Lee BJ, Won CS, Koh JH, Shin JY, Shin YG, Cho BP, Chung CH.

Yonsei Med J. 2007 Apr 30;48(2):301-7.

7.

Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.

Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH, Kim HK, Han JY, Cha DR.

Nephrol Dial Transplant. 2008 Sep;23(9):2750-60. doi: 10.1093/ndt/gfn157. Epub 2008 Apr 3.

8.

Effects of ferulic acid on diabetic nephropathy in a rat model of type 2 diabetes.

Choi R, Kim BH, Naowaboot J, Lee MY, Hyun MR, Cho EJ, Lee ES, Lee EY, Yang YC, Chung CH.

Exp Mol Med. 2011 Dec 31;43(12):676-83. doi: 10.3858/emm.2011.43.12.078.

9.

Effects of alpha-lipoic acid on transforming growth factor beta1-p38 mitogen-activated protein kinase-fibronectin pathway in diabetic nephropathy.

Lee SJ, Kang JG, Ryu OH, Kim CS, Ihm SH, Choi MG, Yoo HJ, Kim DS, Kim TW.

Metabolism. 2009 May;58(5):616-23. doi: 10.1016/j.metabol.2008.12.006.

PMID:
19375583
10.

Abnormal renal structural alterations during the development of diabetes mellitus in Otsuka Long-Evans Tokushima Fatty rats.

Koike T, Tomoda F, Kinuno H, Inoue H, Takata M.

Acta Physiol Scand. 2005 May;184(1):73-81.

PMID:
15847646
11.

Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats.

Kuno Y, Iyoda M, Shibata T, Hirai Y, Akizawa T.

Br J Pharmacol. 2011 Mar;162(6):1389-400. doi: 10.1111/j.1476-5381.2010.01149.x.

12.

Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.

Nishiyama A, Nakagawa T, Kobori H, Nagai Y, Okada N, Konishi Y, Morikawa T, Okumura M, Meda I, Kiyomoto H, Hosomi N, Mori T, Ito S, Imanishi M.

J Hypertens. 2008 Sep;26(9):1849-59. doi: 10.1097/HJH.0b013e3283060efa.

13.

[Renal protective effects of sulodexide in diabetic rats and its anti-oxidative mechanism].

Shu J, Zeng LY, Lin KY, Mu PW, Zhang GC, Chen YM, Wang MM.

Nan Fang Yi Ke Da Xue Xue Bao. 2009 Apr;29(4):778-80. Chinese.

14.

Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.

Lee EY, Kim GT, Hyun M, Kim S, Seok S, Choi R, Lee MY, Chung CH.

Nephrol Dial Transplant. 2012 Nov;27(11):4069-79. doi: 10.1093/ndt/gfs358. Epub 2012 Aug 14.

15.

Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats.

Ogawa M, Hirawa N, Tsuchida T, Eguchi N, Kawabata Y, Numabe A, Negoro H, Hakamada-Taguchi R, Seiki K, Umemura S, Urade Y, Uehara Y.

Nephrol Dial Transplant. 2006 Apr;21(4):924-34. Epub 2005 Dec 29.

16.

Glomerular VEGF resistance induced by PKCδ/SHP-1 activation and contribution to diabetic nephropathy.

Mima A, Kitada M, Geraldes P, Li Q, Matsumoto M, Mizutani K, Qi W, Li C, Leitges M, Rask-Madsen C, King GL.

FASEB J. 2012 Jul;26(7):2963-74. doi: 10.1096/fj.11-202994. Epub 2012 Apr 12.

17.

Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.

Schrijvers BF, De Vriese AS, Tilton RG, Van de Voorde J, Denner L, Lameire NH, Flyvbjerg A.

Horm Metab Res. 2005 Jan;37(1):21-5.

PMID:
15702434
18.

Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.

Lambers Heerspink HJ, Fowler MJ, Volgi J, Reutens AT, Klein I, Herskovits TA, Packham DK, Fraser IR, Schwartz SL, Abaterusso C, Lewis J; Collaborative Study Group.

Diabet Med. 2007 Nov;24(11):1290-5.

PMID:
17956455
19.

A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.

Schrijvers BF, Flyvbjerg A, Tilton RG, Lameire NH, De Vriese AS.

Nephrol Dial Transplant. 2006 Feb;21(2):324-9. Epub 2005 Oct 25.

Items per page

Supplemental Content

Write to the Help Desk